Drug · DIN 02533472
HADLIMA
SINGLE-DOSE PREFILLED SYRINGE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 25, 2023; first marketed October 25, 2023.
- Drug Identification Number (DIN)
- 02533472
- Company (DIN owner)
- Samsung Bioepis Co., LtdIncheon, Incheon, Korea, Republic Of
- Schedule
- Schedule d; Prescription
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Adalimumab L04AB04
- Class
- Human
- Record last updated
- August 10, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ADALIMUMAB | 40 MG | 0.4 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- December 14, 2022: NOC 29713Supplement to a New Drug Submission (SNDS) · New strength
Other DINs named HADLIMA
- DIN 02473097 · Marketed